Articles

Articles 18 registres trobats  anterior11 - 18  anar al registre: La cerca s'ha fet en 0.01 segons. 
11.
10 p, 2.7 MB A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer / Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ; Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ; Planchard, David (Institut Gustave Roussy (Villejuif, França)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ; Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ; Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ; Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ; Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ; Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ; Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ; Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ; Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ; Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597  
12.
1 p, 789.3 KB Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Institut Català d'Oncologia) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576  
13.
13 p, 2.1 MB Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study / Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ; Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ; Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ; Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ; de Castro, Javier (Hospital Universitario La Paz (Madrid)) ; Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ; Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ; Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ; Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ; Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Sansano, Irene (Hospital Universitari Vall d'Hebron) ; Garcia, Felip (Quironsalud Hospital) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Mancheño, Nuria (Hospital Universitari i Politècnic La Fe (València)) ; Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ; Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ; Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ; Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ; Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ; Abdulkader, Ihab (Complejo Hospitalario Universitario de Santiago de Compostela) ; Garcia-Gonzalez, Jorge (Complejo Hospitalario Universitario de Santiago de Compostela) ; Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ; Rodríguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ; Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Gonzalez-Piñeiro, Ana (Hospital Álvaro Cunqueiro (Vigo)) ; Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ; Lozano, María Dolores (Clínica Universidad de Navarra) ; Gurpide, Alfonso (Clínica Universidad de Navarra) ; Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ; Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ; Company, Amparo (Hospital Clínic Universitari (València)) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ; Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Álvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ; Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ; Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ; Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ; Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ; Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132  
14.
8 p, 713.1 KB Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer / Sanz-Santos, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Serra Mitjà, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ; Andreo García, Felipe (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Torky, Mohamed (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Centeno, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fernández Araujo, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Reina, Samuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ruiz Manzano, J.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The present study sought to evaluate the usefulness of EBUS-TBNA in the diagnosis of locoregional recurrence of lung cancer in a cohort of lung cancer patients who were previously treated surgically, and describe our initial experience of EUS-B-FNA in this clinical scenario. [...]
2017 - 10.1186/s12890-017-0388-4
BMC Pulmonary Medicine, Vol. 17 (february 2017)  
15.
8 p, 738.8 KB The epidermal growth factor receptor (EGRF) in lung cancer / Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Capdevila, Laia (Hospital Sant Pau i Santa Tecla (Tarragona)) ; Cros Costa, Sara (Hospital General de Granollers) ; Vilà, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; de los Llanos Gil, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Remón, Jordi (Hospital de Mataró. Consorci Sanitari del Maresme) ; Rosell, Rafael (Fundación Molecular Oncology Research) ; Universitat Autònoma de Barcelona
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. [...]
2015 - 10.1186/s40247-015-0013-z
Translational Respiratory Medicine, Vol. 3 (february 2015)  
16.
8 p, 455.0 KB Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A. (University of Toronto) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)  
17.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  
18.
2 p, 227.2 KB Estudis sobre càncer de pulmó a la població espanyola milloren el tractament individualitzat / Morán, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina) ; Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina)
Abans d'aquest estudi, només s'havia analitzat prospectivament la presència de mutacions de l'oncogen EGFR per a l'adenocarcinoma en població asiàtica. Els investigadors han estudiat la incidència d'aquesta malaltia en població espanyola i la seva resposta al tractament amb erlotinib. [...]
Antes de este estudio, sólo se había analizado prospectivamente la presencia de mutaciones del oncogén EGFR para el adenocarcinoma en población asiática. Los investigadores han estudiado la incidencia de esta enfermedad en la población española y su respuesta al tratamiento con erlotinib. [...]

2010
UAB divulga, Febrer 2010, p. 1-2
2 documents

Articles : 18 registres trobats   anterior11 - 18  anar al registre:
Vegeu també: autors amb noms similars
5 Moran, T.
3 Moran, T. J..
18 Moran, Teresa
5 Morán, T.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.